TABLE 3.
AASLD/IDSA/IAS-USA HCV Treatment Recommendations for Treatment-Naïve Patients and Retreatment in Patients for Whom Prior PEG-IFN and RBV Therapy Has Failed
| Treatment-Naïve | ||
|---|---|---|
| Genotype | Regimen | Duration |
| Genotype 1a | ledipasvir/sofosbuvir | 12 weeks |
| paritaprevir/ritonavir/ombitasvir + dasabuvir + RBV | 12 weeks (no cirrhosis) 24 weeks (cirrhosis) |
|
| simeprevir + sofosbuvir ± RBV | 12 weeks (no cirrhosis) 24 weeks (cirrhosis without Q80K polymorphism) |
|
| Genotype 1b | ledipasvir/sofosbuvir | 12 weeks |
| paritaprevir/ritonavir/ombitasvir + dasabuvir paritaprevir/ritonavir/ombitasvir + dasabuvir + RBV |
12 weeks (no cirrhosis) 12 weeks (cirrhosis) |
|
| simeprevir + sofosbuvir simeprevir + sofosbuvir ± RBV |
12 weeks (no cirrhosis) 24 weeks (cirrhosis) |
|
| Genotype 2 | sofosbuvir + RBV | 12 weeks (no cirrhosis) 16 weeks (cirrhosis) |
| Genotype 3 | sofosbuvir + RBV + PEG-IFN sofosbuvir + RBV (alternative regimen) |
12 weeks 24 weeks |
| Retreatment for Prior Treatment Failure with Peg-IFN plus RBV | ||
| Genotype | Regimen | Duration |
| Genotype 1a (no cirrhosis) | ledipasvir/sofosbuvir | 12 weeks |
| paritaprevir/ritonavir/ombitasvir + dasabuvir + RBV | 12 weeks | |
| simeprevir + sofosbuvir | 12 weeks | |
| Genotype 1b (no cirrhosis) | ledipasvir/sofosbuvir | 12 weeks |
| paritaprevir/ritonavir/ombitasvir + dasabuvir | 12 weeks | |
| simeprevir + sofosbuvir | 12 weeks | |
| Genotype 1a or 1b (compensated cirrhosis) | ledipasvir/sofosbuvir ledipasvir/sofosbuvir+ RBV |
24 weeks 12 weeks |
| paritaprevir/ritonavir/ombitasvir + dasabuvir + RBV |
24 weeks (genotype 1a) 12 weeks (genotype 1b) |
|
| simeprevir + sofosbuvir ± RBV | 24 weeks (without Q80K polymorphism) | |
| Genotype 2 | sofosbuvir + RBV sofosbuvir + RBV + PEG-IFN |
12-16 weeks 12 weeks |
| Genotype 3 | sofosbuvir + RBV + PEG-IFN sofosbuvir + RBV (alternative for IFN ineligible) |
12 weeks 24 weeks |
Note: Recommendations accessed on July 16, 2015.2
PEG-IFN = pegylated interferon; RBV = ribavirin.